BradleyMBlockMD

Family Medicine • Oviedo, FL

Physician

Join to view full profile

Dr. Block is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Block's full profile

Already have an account?

Office
2441 West State Road 426
Suite 2011
Oviedo, FL 32765
Phone+1 407-678-6888

Fax+1 407-359-5454
Is this information wrong?

Education & Training

Geisinger Health SystemResidency, Family Medicine, 1989 - 1992
Lewis Katz School of Medicine at Temple UniversityClass of 1989

Certifications & Licensure

FL State Medical License 1992 - 2025
PA State Medical License 1991 - 1998
American Board of Family Medicine Family Medicine

Awards, Honors, & Recognition

Fellow (FAAFP) American Academy of Family Physicians, 2011
CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2013

Clinical Trials

Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism Start of enrollment: 2011 Sep 01
Completed
Phase 3
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes Start of enrollment: 2014 Apr 01
Completed
Phase 2
Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL Start of enrollment: 2017 Apr 06
Suspended
Phase 2
A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke Start of enrollment: 2019 Dec 17
Completed
Phase 4
Join now to see all

Publications & Presentations

PubMed

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators> ;The New England journal of medicine. 2021-06-25
10 citations
A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus
Moon Kyu Lee, Sin Gon Kim, Elaine Watkins, Min Kyong Moon, Sang Youl Rhee, Juan Pablo Frias, Choon Hee Chung, Seung-Hwan Lee, Bradley Block, Bong Soo Cha, Hyeong Kyu P...> ;Journal of Diabetes and Its Complications. 2020 May 1
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B,...> ;The New England journal of medicine. 2016-11-13
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Pate...> ;The New England journal of medicine. 2018-08-26
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD...> ;The New England journal of medicine.
Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M, NAC-MD-01 Study Investigators> ;Lancet (London, England).
48 citations
Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study
Patrick J. Strollo, Jan Hedner, Nancy A. Collop, Daniel G. Lorch, Dan Chen, Lawrence P. Carter, Yuan Lu, Lawrence Lee, Jed Black, Jean-Louis Pépin, Susan Redline, Mark...> ;Chest. 2019 Feb 1
55 citations
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Lancet. 2018 Nov 24
Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.
Buse JB, Rodbard HW, Trescoli Serrano C, Luo J, Ivanyi T, Bue-Valleskey J, Hartman ML, Carey MA, Chang AM, IMAGINE 5 Investigators> ;Diabetes care. 2015-11-17
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ...
Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM, ODYSSEY COMBO II Investigators> ;European heart journal. 2015-02-16
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled tria...
Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD, on behalf of the EDITION 3 study investigators> ;Diabetes, obesity & metabolism. 2015-02-12
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide ve...
Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probst...> ;American heart journal. 2015-02-12
Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P, TIOSPIR Investigators> ;The New England journal of medicine. 2013-08-30
1 citations
How we improved our practice and our bottom line with a new EMR system.
Bradley M. Block> ;Family Practice Management. 2008 Jul 1
Join now to see all